Abnormalities in thrombin-antithrombin pathway in AL amyloidosis

G. Gamba, N. Montani, E. Anesi, G. Palladini, F. Lorenzutti, V. Perfetti, G. Merlini

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Various pathogenic factors have been proposed to explain the abnormal hemostasis observed in AL amyloidosis. Since imbalance between clotting factors and inhibitors could play a pathogenic role in both hemorrhagic and thrombotic manifestations, we investigated the thrombin-antithrombin pathway in 35 patients with AL amyloidosis. Ten patients suffered from bleeding while 3 patients experienced deep venous thrombosis. Thrombin time was prolonged in 29 subjects, the mean values of antithrombin III activity (ATIII Act) were significantly lower than those of antithrombin III antigen (ATIII Ag) with loss of relationship between these two different techniques of ATIII detection, normally observed in healthy controls. In 19 patients increased levels of thrombin-antithrombin (TAT) complexes were present. Crossed immunoelectrophoresis of ATIII, performed in presence of heparin, evidenced ATIII forms with reduced binding capacity to heparin and TAT complexes of various electrophoretic mobilities. In conclusion, the impairment of the thrombin-antithrombin pathway, in association with the low ATIII biological activity, might play a pathogenic role in the hypercoagulable state reported in AL amyloidosis, despite the higher frequency of bleeding manifestations.

Original languageEnglish
Pages (from-to)273-277
Number of pages5
JournalAmyloid
Volume6
Issue number4
Publication statusPublished - 1999

Fingerprint

Antithrombins
Amyloidosis
Thrombin
Antithrombin III
Heparin
Hemorrhage
Two-Dimensional Immunoelectrophoresis
Thrombin Time
Blood Coagulation Factors
Hemostasis
Venous Thrombosis
Antigens
antithrombin III-protease complex

Keywords

  • AL amyloidosis
  • Antithrombin III
  • Clotting abnormalities
  • Hemostasis
  • Protease inhibitors
  • Thrombin-antithrombin complexes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. / Gamba, G.; Montani, N.; Anesi, E.; Palladini, G.; Lorenzutti, F.; Perfetti, V.; Merlini, G.

In: Amyloid, Vol. 6, No. 4, 1999, p. 273-277.

Research output: Contribution to journalArticle

@article{11bc09a615e149019bae1267a40ef132,
title = "Abnormalities in thrombin-antithrombin pathway in AL amyloidosis",
abstract = "Various pathogenic factors have been proposed to explain the abnormal hemostasis observed in AL amyloidosis. Since imbalance between clotting factors and inhibitors could play a pathogenic role in both hemorrhagic and thrombotic manifestations, we investigated the thrombin-antithrombin pathway in 35 patients with AL amyloidosis. Ten patients suffered from bleeding while 3 patients experienced deep venous thrombosis. Thrombin time was prolonged in 29 subjects, the mean values of antithrombin III activity (ATIII Act) were significantly lower than those of antithrombin III antigen (ATIII Ag) with loss of relationship between these two different techniques of ATIII detection, normally observed in healthy controls. In 19 patients increased levels of thrombin-antithrombin (TAT) complexes were present. Crossed immunoelectrophoresis of ATIII, performed in presence of heparin, evidenced ATIII forms with reduced binding capacity to heparin and TAT complexes of various electrophoretic mobilities. In conclusion, the impairment of the thrombin-antithrombin pathway, in association with the low ATIII biological activity, might play a pathogenic role in the hypercoagulable state reported in AL amyloidosis, despite the higher frequency of bleeding manifestations.",
keywords = "AL amyloidosis, Antithrombin III, Clotting abnormalities, Hemostasis, Protease inhibitors, Thrombin-antithrombin complexes",
author = "G. Gamba and N. Montani and E. Anesi and G. Palladini and F. Lorenzutti and V. Perfetti and G. Merlini",
year = "1999",
language = "English",
volume = "6",
pages = "273--277",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Abnormalities in thrombin-antithrombin pathway in AL amyloidosis

AU - Gamba, G.

AU - Montani, N.

AU - Anesi, E.

AU - Palladini, G.

AU - Lorenzutti, F.

AU - Perfetti, V.

AU - Merlini, G.

PY - 1999

Y1 - 1999

N2 - Various pathogenic factors have been proposed to explain the abnormal hemostasis observed in AL amyloidosis. Since imbalance between clotting factors and inhibitors could play a pathogenic role in both hemorrhagic and thrombotic manifestations, we investigated the thrombin-antithrombin pathway in 35 patients with AL amyloidosis. Ten patients suffered from bleeding while 3 patients experienced deep venous thrombosis. Thrombin time was prolonged in 29 subjects, the mean values of antithrombin III activity (ATIII Act) were significantly lower than those of antithrombin III antigen (ATIII Ag) with loss of relationship between these two different techniques of ATIII detection, normally observed in healthy controls. In 19 patients increased levels of thrombin-antithrombin (TAT) complexes were present. Crossed immunoelectrophoresis of ATIII, performed in presence of heparin, evidenced ATIII forms with reduced binding capacity to heparin and TAT complexes of various electrophoretic mobilities. In conclusion, the impairment of the thrombin-antithrombin pathway, in association with the low ATIII biological activity, might play a pathogenic role in the hypercoagulable state reported in AL amyloidosis, despite the higher frequency of bleeding manifestations.

AB - Various pathogenic factors have been proposed to explain the abnormal hemostasis observed in AL amyloidosis. Since imbalance between clotting factors and inhibitors could play a pathogenic role in both hemorrhagic and thrombotic manifestations, we investigated the thrombin-antithrombin pathway in 35 patients with AL amyloidosis. Ten patients suffered from bleeding while 3 patients experienced deep venous thrombosis. Thrombin time was prolonged in 29 subjects, the mean values of antithrombin III activity (ATIII Act) were significantly lower than those of antithrombin III antigen (ATIII Ag) with loss of relationship between these two different techniques of ATIII detection, normally observed in healthy controls. In 19 patients increased levels of thrombin-antithrombin (TAT) complexes were present. Crossed immunoelectrophoresis of ATIII, performed in presence of heparin, evidenced ATIII forms with reduced binding capacity to heparin and TAT complexes of various electrophoretic mobilities. In conclusion, the impairment of the thrombin-antithrombin pathway, in association with the low ATIII biological activity, might play a pathogenic role in the hypercoagulable state reported in AL amyloidosis, despite the higher frequency of bleeding manifestations.

KW - AL amyloidosis

KW - Antithrombin III

KW - Clotting abnormalities

KW - Hemostasis

KW - Protease inhibitors

KW - Thrombin-antithrombin complexes

UR - http://www.scopus.com/inward/record.url?scp=0033405473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033405473&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 273

EP - 277

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

IS - 4

ER -